S

Sichuan Kelun-Biotech Biopharmaceutical Co Ltd
HKEX:6990

Watchlist Manager
Sichuan Kelun-Biotech Biopharmaceutical Co Ltd
HKEX:6990
Watchlist
Price: 173.2 HKD -3.02% Market Closed
Market Cap: 38.6B HKD
Have any thoughts about
Sichuan Kelun-Biotech Biopharmaceutical Co Ltd?
Write Note
Section:
 

Relative Value

The Relative Value of one Sichuan Kelun-Biotech Biopharmaceutical Co Ltd stock under the Base Case scenario is 145.05 HKD. Compared to the current market price of 173.2 HKD, Sichuan Kelun-Biotech Biopharmaceutical Co Ltd is Overvalued by 16%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

Relative Value
Base Case
145.05 HKD
Overvaluation 16%
Relative Value
Price
S
Worst Case
Base Case
Best Case

Valuation Multiples

19.3
P/S
P/S
Price to Sales
19.3
vs History
16
vs Industry
31
Median 3Y
17.4
Median 5Y
17.4
Industry
7.6
Forward
19.5
More Details
Negative
P/E
P/E
Price to Earnings
N/A
vs History
vs Industry
Median 3Y
-155.2
Median 5Y
-155.2
Industry
22.1
Forward
-119.1
More Details
608.1
P/OCF
P/OCF
Price to OCF
608.1
vs History
0
vs Industry
0
Median 3Y
527.1
Median 5Y
527.1
Industry
21.9
More Details
Negative
P/FCFE
P/FCFE
Price to FCFE
N/A
vs History
vs Industry
0
Median 3Y
-63.3
Median 5Y
-63.3
Industry
23.4
More Details
11.3
P/B
P/B
Price to Book Value
11.3
vs History
16
vs Industry
6
Median 3Y
10.2
Median 5Y
10.2
Industry
2.5
More Details
17.8
EV/S
EV/S
Enterprise Value to Sales
17.8
vs History
16
vs Industry
28
Median 3Y
15.9
Median 5Y
15.9
Industry
7.5
Forward
17.9
More Details
28.7
EV/GP
EV/GP
Enterprise Value to Gross Profit
28.7
vs History
16
vs Industry
16
Median 3Y
25.7
Median 5Y
25.7
Industry
9.3
More Details
Negative
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
N/A
vs History
vs Industry
Median 3Y
-76.4
Median 5Y
-76.4
Industry
4.2
Forward
-157.2
More Details
Negative
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
N/A
vs History
vs Industry
Median 3Y
-181
Median 5Y
-181
Industry
4
Forward
-151.3
More Details
559.7
EV/OCF
EV/OCF
Enterprise Value to OCF
559.7
vs History
0
vs Industry
0
Median 3Y
485.4
Median 5Y
485.4
Industry
5.9
More Details
Negative
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
N/A
vs History
vs Industry
Median 3Y
-1 274.1
Median 5Y
-1 274.1
Industry
3.9
More Details
928.6
EV/IC
EV/IC
Enterprise Value to IC
928.6
vs History
0
vs Industry
6
Median 3Y
46.9
Median 5Y
46.9
Industry
4.5
More Details

Multiples Across Competitors

Competitors Multiples
Sichuan Kelun-Biotech Biopharmaceutical Co Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
CN
Sichuan Kelun-Biotech Biopharmaceutical Co Ltd
HKEX:6990
38.6B HKD 19.3 -155.6 -307.1 -181.5
FR
Pharnext SCA
OTC:PNEXF
6T USD 38 027 714.7 -180 740.1 -219 476 -216 971.5
US
Abbvie Inc
NYSE:ABBV
310.3B USD 5.6 61.1 15.2 23.4
US
Amgen Inc
NASDAQ:AMGN
141.6B USD 4.4 33.5 16 30.4
US
Gilead Sciences Inc
NASDAQ:GILD
115.3B USD 4.1 915.4 10.2 10.2
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
102.4B USD 9.6 -213.4 21 22.1
US
Epizyme Inc
F:EPE
94.1B EUR 1 852.6 -472.7 -514.8 -501.1
AU
CSL Ltd
ASX:CSL
134.4B AUD 5.7 31.8 19.7 24.6
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
77.3B USD 5.6 16.6 15.1 16.7
US
Seagen Inc
F:SGT
39.3B EUR 17.8 -54.7 -58.8 -53
NL
argenx SE
XBRU:ARGX
35.8B EUR 19.2 -134.7 -108.8 -79.3
P/S Multiple
Revenue Growth P/S to Growth
CN
S
Sichuan Kelun-Biotech Biopharmaceutical Co Ltd
HKEX:6990
Average P/S: 3 457 241.7
19.3
64%
0.3
FR
Pharnext SCA
OTC:PNEXF
38 027 714.7
N/A N/A
US
Abbvie Inc
NYSE:ABBV
5.6
20%
0.3
US
Amgen Inc
NASDAQ:AMGN
4.4
26%
0.2
US
Gilead Sciences Inc
NASDAQ:GILD
4.1
10%
0.4
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
9.6
34%
0.3
US
E
Epizyme Inc
F:EPE
1 852.6
N/A N/A
AU
CSL Ltd
ASX:CSL
5.7
23%
0.2
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
5.6
23%
0.2
US
S
Seagen Inc
F:SGT
17.8
118%
0.2
NL
argenx SE
XBRU:ARGX
19.2
220%
0.1
P/E Multiple
Earnings Growth P/E to Growth
CN
S
Sichuan Kelun-Biotech Biopharmaceutical Co Ltd
HKEX:6990
Average P/E: 211.7
Negative Multiple: -155.6 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -180 740.1 N/A N/A
US
Abbvie Inc
NYSE:ABBV
61.1
413%
0.1
US
Amgen Inc
NASDAQ:AMGN
33.5
73%
0.5
US
Gilead Sciences Inc
NASDAQ:GILD
915.4
77%
11.9
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -213.4
48%
N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -472.7 N/A N/A
AU
CSL Ltd
ASX:CSL
31.8
65%
0.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16.6
44%
0.4
US
S
Seagen Inc
F:SGT
Negative Multiple: -54.7 N/A N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -134.7 N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
CN
S
Sichuan Kelun-Biotech Biopharmaceutical Co Ltd
HKEX:6990
Average EV/EBITDA: 16.2
Negative Multiple: -307.1 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -219 476 N/A N/A
US
Abbvie Inc
NYSE:ABBV
15.2
29%
0.5
US
Amgen Inc
NASDAQ:AMGN
16
62%
0.3
US
Gilead Sciences Inc
NASDAQ:GILD
10.2
16%
0.6
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
21
43%
0.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -514.8 N/A N/A
AU
CSL Ltd
ASX:CSL
19.7
42%
0.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
15.1
35%
0.4
US
S
Seagen Inc
F:SGT
Negative Multiple: -58.8 N/A N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -108.8 N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
CN
S
Sichuan Kelun-Biotech Biopharmaceutical Co Ltd
HKEX:6990
Average EV/EBIT: 21.2
Negative Multiple: -181.5 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -216 971.5 N/A N/A
US
Abbvie Inc
NYSE:ABBV
23.4
90%
0.3
US
Amgen Inc
NASDAQ:AMGN
30.4
90%
0.3
US
Gilead Sciences Inc
NASDAQ:GILD
10.2
32%
0.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
22.1
45%
0.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -501.1 N/A N/A
AU
CSL Ltd
ASX:CSL
24.6
54%
0.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16.7
42%
0.4
US
S
Seagen Inc
F:SGT
Negative Multiple: -53 N/A N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -79.3 N/A N/A

See Also

Summary
Intrinsic value, competitors valuation, and company profile.
DCF Valuation
Stock valuation using Discount Cash Flow valuation method.
Relative Valuation
Stock valuation using valuation multiples.
Wall Street Estimates
Price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
Stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 210,300+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.